<DOC>
	<DOCNO>NCT01856751</DOCNO>
	<brief_summary>Occurrence inhibitor coagulation factor VIII diagnose ~30 % patient haemophilia A . Presence inhibitor titre &gt; 5 BU/ml require use by-passing agent : recombinant activate Factor VIIa concentrate ( rFVIIa ) and/or activate prothrombin complex concentrate ( APCC ) . Similarly , haemorrhagic complication patient acquire haemophilia inhibitor titre &gt; 5 BU/ml treat by-passing agent . Response treatment by-passing agent patient-specific , vary patient subsequent bleeding . Some patient good response product , however patient well bleed control provide one mention agent ( APCC rFVIIa ) . There clinical situation severe bleeding require alternate use agent . Traditional method laboratory test use post-treatment patient haemophilia without inhibitor useless presence inhibitor . Laboratory monitor therapy by-passing agent possible use global test coagulation process assessment , follow : thrombin generation assay ( TGA ) thromboelastometry ( TEM ) . Several study reveal TGA allow monitor therapy by-passing agent patient haemophilia A inhibitor - choice effective treatment option - agent type dose , well laboratory assessment treatment efficacy . Up date , laboratory test assess efficacy by-passing agent patient acquire haemophilia conduct . In Factor VIII IX deficiency condition , fibrin 's fibre generate thrombin morphologically thicker , blood clot increase susceptibility fibrinolytic enzyme . Blood clot stability may assess use thromboelastometry ( TEM ) . We hypothesize simultaneous use TGA TEM method may allow assessment patient 's individual response therapy by-passing agent . Clinical significance minimal dose APCC rFVIIa , need TGA TEM normalization , require study . Tests ' purpose : Examination hypothesis simultaneous use thrombin generation assay ( TGA ) thromboelastometry ( TEM ) may facilitate choice optimal therapy by-passing agent laboratory monitor efficacy agent patient acquire haemophilia haemophilia A inhibitor .</brief_summary>
	<brief_title>Use TGA TEM Assessment Efficacy Treatment With APCC rFVIIa</brief_title>
	<detailed_description>This section Not applicable</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<criteria>patient acquire haemophilia patient congenital haemophilia A inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Haemophilia</keyword>
	<keyword>TGA</keyword>
	<keyword>TEM</keyword>
</DOC>